Quartz Partners LLC Makes New $1.61 Million Investment in ANI Pharmaceuticals, Inc. $ANIP
Quartz Partners LLC has invested $1.61 million in ANI Pharmaceuticals, acquiring 19,424 shares, joining other institutional investors who have increased their holdings. ANI Pharmaceuticals exceeded Q2 earnings expectations with $2.21 EPS and $266.04 million in revenue, leading to a positive outlook with fiscal 2026 EPS guidance of $9.19–$9.69, despite some recent analyst downgrades. The company's stock currently holds a "Moderate Buy" consensus rating and a $105.83 price target.
Great Lakes Advisors LLC Buys Shares of 61,481 ANI Pharmaceuticals, Inc. $ANIP
Great Lakes Advisors LLC has purchased 61,481 shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), valued at approximately $5.1 million, making them a new institutional investor in the company. This comes as ANI Pharmaceuticals exceeded quarterly earnings expectations, reporting adjusted EPS of $2.21 and revenue of $266.04 million, a 25.8% year-over-year increase. Despite a "Moderate Buy" consensus rating from analysts, some firms have recently downgraded ratings or reduced price targets for the specialty pharmaceutical company.
Aurora Investment Counsel Takes Position in ANI Pharmaceuticals, Inc. $ANIP
Aurora Investment Counsel has acquired a new stake of 26,890 shares in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the second quarter, valued at approximately $2.23 million. This comes as several other institutional investors have also adjusted their holdings in the specialty pharmaceutical company. ANI Pharmaceuticals recently reported strong Q2 earnings, beating analyst expectations, and has a "Moderate Buy" consensus rating from analysts with a target price of $105.83.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of "Moderate Buy" from Brokerages
ANI Pharmaceuticals (NASDAQ:ANIP) has received an average "Moderate Buy" rating from eight brokerages, with four buy and four hold ratings. The company's average 12-month price target is $105.83, exceeding its current share price of $76.87. Recent quarterly results surpassed expectations, reporting $2.21 EPS against an estimated $2.04, and a 25.8% revenue increase year-over-year to $266.04 million.
ANI Pharmaceuticals (ANIP) Could Be 34% Undervalued As Earnings And Guidance Hold
ANI Pharmaceuticals (ANIP) is currently in focus after reporting its Q2 and H1 2026 results and reaffirming its full-year net revenue outlook of $1,080 million to $1,140 million. Despite recent strong earnings, the stock has seen a short-term decline, though it shows significant long-term gains over five years. The company is considered 33.7% undervalued with a fair value estimate of $112.71, driven by potential growth in Cortrophin Gel across various indications, but faces risks like competition and pricing pressures.
Walleye Capital LLC Buys Shares of 106,112 ANI Pharmaceuticals, Inc. $ANIP
Walleye Capital LLC has acquired a new position in ANI Pharmaceuticals, purchasing 106,112 shares valued at approximately $8.8 million, indicating growing institutional interest as hedge funds and other investors collectively own 76.05% of the company. ANI Pharmaceuticals recently surpassed quarterly earnings expectations, reporting adjusted EPS of $2.21 against a consensus of $2.04 and a 25.8% increase in revenue year-over-year. Despite some analyst ratings being lowered from "strong-buy" to "buy" or "hold," the company maintains a "Moderate Buy" consensus rating with an average price target of $105.83, while shares are trading at $76.54.
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
ANI Pharmaceuticals (ANIP) presents an attractive valuation and growth profile, trading at a significant discount compared to benchmarks and showing strong projected double-digit sales and earnings growth for 2026. However, the company faces substantial execution risk due to its heavy reliance on Cortrophin Gel for revenue, which accounts for nearly half of total revenues. Despite strong growth and value scores, ANIP currently holds a Zacks Rank #4 (Sell) due to near-term concerns about achieving Cortrophin revenue targets and a slight downward revision in current-fiscal-year EPS estimates.
The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q2 Earnings Call
ANI Pharmaceuticals reported strong Q2 year-on-year growth in its rare disease and generics businesses, exceeding analyst estimates for revenue, EPS, and EBITDA, though the market reacted negatively. CEO Nikhil Lalwani highlighted significant momentum in demand for Cortrophin Gel. Analysts focused on the gout expansion, prescription data disconnects, revised Cortrophin guidance, conversion of new cases to prescriptions, and the impact of insurance reverification issues.
ANI Pharmaceuticals (ANIP) Insider Sell: SR. VP, GENERAL COUNSEL & SEC. Meredith Cook Sells 500 Shares
Meredith Cook, SR. VP, General Counsel & Secretary of ANI Pharmaceuticals (ANIP), sold 500 shares of the company stock for approximately $37,740. This transaction is part of a broader trend of insider selling at ANI Pharmaceuticals, with 48 insider sells and zero buys over the past year. Despite this, GuruFocus valuation model indicates the stock is modestly undervalued, trading at $75.48 against a GF Value of $96.55.
ANI Pharmaceuticals (ANIP) counsel Meredith Cook sells 500 shares under 10b5-1 plan
Meredith Cook, Senior Vice President, General Counsel and Secretary at ANI Pharmaceuticals (ANIP), sold 500 shares of common stock at $75.48 per share on August 13, 2026. This transaction was conducted under a Rule 10b5-1 trading plan adopted in September 2025. Following the sale, Cook directly holds 74,424 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals Senior VP Meredith Cook Sells 500 Shares via 10b5-1 Trading Plan
Meredith Cook, Senior Vice President, General Counsel, and Secretary of ANI Pharmaceuticals Inc (NASDAQ:ANIP), sold 500 shares of the company's common stock on August 13, 2026. The sale, executed under a pre-established Rule 10b5-1 trading plan adopted on September 15, 2025, occurred at a price of $75.48 per share. Following this transaction, Cook directly retains 74,424 shares of ANI Pharmaceuticals common stock.
Amundi Has $352,000 Holdings in ANI Pharmaceuticals, Inc. $ANIP
Amundi significantly reduced its stake in ANI Pharmaceuticals by 93% in Q1, selling 61,159 shares and retaining 4,571 shares worth $352,000. Despite Amundi's divestment, other institutional investors like Balyasny, Rubric Capital, UBS, and Schonfeld substantially increased their positions, with institutional ownership now at 76.05%. ANI Pharmaceuticals reported strong quarterly results, exceeding EPS and revenue expectations, and analysts maintain a "Moderate Buy" consensus with a $105.83 price target.
Ani Pharmaceuticals SVP Ori Gutwerg sells $243,474 in common stock.
Ori Gutwerg, SVP of Generics at ANI Pharmaceuticals Inc. (NASDAQ:ANIP), sold 3,162 shares of common stock for $243,474 on August 10, 2026. Following the sale, Gutwerg directly holds 75,534 shares. This transaction comes as the company's stock trades near its 52-week low, and after recent mixed financial results where strong earnings were offset by underperformance in the Cortrophin product.
Ori Gutwerg Sells 3,162 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock
Ori Gutwerg, Senior Vice President of ANI Pharmaceuticals, sold 3,162 shares of ANIP stock for a total of $243,474 on August 10th. This transaction reduced his holding by 4.02%, leaving him with 75,534 shares. Despite the insider sale and a slight dip in stock price, analysts maintain a "Moderate Buy" rating for ANIP, with the company having recently exceeded quarterly earnings and revenue expectations.
Ani Pharmaceuticals SVP Ori Gutwerg sells $243,474 in common stock. By Investing.com
Ori Gutwerg, SVP of Generics at ANI Pharmaceuticals Inc., sold 3,162 shares of common stock for $243,474 on August 10, 2026, reducing his direct holdings to 75,534 shares. This transaction occurred as the stock trades near its 52-week low. The company recently reported strong Q2 2026 results with adjusted EPS surpassing estimates, despite a downward revision in full-year Cortrophin guidance, leading to mixed analyst reactions.
ANI Pharma SVP, Generics Ori Gutwerg reports sale of 3,162 common shares worth $243,474
Ori Gutwerg, SVP of Generics at ANI Pharmaceuticals, sold 3,162 common shares for $77 each on August 10, totaling $243,474. This transaction reduced his holdings to 75,534 common shares. The information for this report was generated by AI from an SEC filing.
ANI Pharmaceuticals (ANIP) SVP Ori Gutwerg sells 3,162 shares at $77
Ori Gutwerg, Senior Vice President of Generics at ANI Pharmaceuticals Inc. (ANIP), sold 3,162 shares of common stock at $77.00 per share on August 10, 2026. Following this transaction, Gutwerg directly holds 75,534 shares of the company's common stock. The sale, valued at $243,000, was executed in an open market or private transaction.
Canaccord Genuity Group Cuts ANI Pharmaceuticals (NASDAQ:ANIP) Price Target to $90.00
Canaccord Genuity Group has lowered its price target for ANI Pharmaceuticals (NASDAQ:ANIP) to $90.00 from $91.00, while maintaining a "hold" rating. This implies a potential upside of 15% from the previous closing price. The company recently surpassed quarterly earnings expectations, reporting adjusted EPS of $2.21 and revenue of $266.04 million, a 25.8% increase year-over-year.
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Lowered by Wall Street Zen
ANI Pharmaceuticals (NASDAQ:ANIP) recently had its stock rating lowered from "strong buy" to "buy" by Wall Street Zen, though the broader analyst consensus remains a "Moderate Buy" with an average target price of $106.83. This downgrade follows strong second-quarter results where the company exceeded EPS and revenue estimates, driven by a significant increase in Cortrophin Gel sales. Despite reaffirming its overall 2026 financial outlook, ANI Pharmaceuticals did lower its Cortrophin Gel revenue target, and experienced a decline in margins and revenue for ILUVIEN and Brands.
ANI Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $109.12, Implies 32% Upside
Analysts have revised their average 12-month price target for ANI Pharmaceuticals, Inc. (ANIP) stock down slightly from $110 to $109.12, with a range of $91 to $124. This new target suggests a potential upside of approximately 32% from its August 6th closing price. The consensus rating from 8 analysts remains a "Buy," with 7 recommending Buy and 1 recommending Hold.
ANI Pharmaceuticals 2026: Revenue $266.04M, EPS $1.05— 10-Q Summary
ANI Pharmaceuticals reported strong second-quarter 2026 results, with revenue reaching $266.04 million and diluted EPS at $1.05. This growth was primarily driven by significant volume gains in its Rare Disease segment, particularly Cortrophin Gel, and increased generics volume. The company also saw a substantial increase in net income, rising to $24.71 million from $8.55 million in the prior year.
ANI Pharmaceuticals, Inc (ANIP) Q2 2026 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (ANIP) reported record Q2 2026 revenues of $266 million and adjusted EBITDA of $71.6 million, driven by strong performance in its rare disease and generics businesses. The company is transforming into a leading rare disease company, with Cortrophin Gel revenues up 43% year-over-year, and has expanded its sales force by 50% to target gouty arthritis flares. ANI revised its full-year Cortrophin Gel revenue guidance to $520 million to $540 million, while reaffirming overall revenue and adjusted EBITDA guidance, expecting significant growth in the second half of 2026.
Earnings call transcript: ANI Pharmaceuticals beats Q2 2026 estimates, shares fall premarket
ANI Pharmaceuticals reported stronger-than-expected Q2 2026 results, with adjusted EPS of $2.21 and record revenue of $266 million, surpassing analyst estimates. Despite the beat, the stock fell in premarket trading due to investor focus on the company's outlook, declining gross margins, and a revised Cortrophin revenue guidance for the full year. The company emphasized strong growth in its Cortrophin Gel sales, especially from its new gout-focused sales force, and maintained its full-year EBITDA and EPS guidance, expecting operational leverage in 2027.
ANI Pharmaceuticals Releases Q2 2026 Financial Results
ANI Pharmaceuticals, Inc. reported strong Q2 2026 financial results, with adjusted diluted EPS of $2.21, beating analyst estimates, and revenue of $266.0M, a 25.9% increase year-over-year. The company's flagship product, Cortrophin Gel, was a key growth driver, and management provided optimistic full-year EPS guidance. Wall Street maintains a favorable outlook with multiple buy ratings.
ANI Pharmaceuticals, Inc (ANIP) Q2 2026 Earnings Call Transcript
ANI Pharmaceuticals (ANIP) reported record Q2 2026 revenues of $266 million, driven by a 26% year-over-year increase, primarily due to strong performance in its rare disease and generics segments, and an out-licensing deal. The company achieved record Cortrophin revenues of $117.1 million and adjusted EBITDA of $71.6 million. ANI also expanded its rare disease sales force by 50% and revised its full-year Cortrophin gel revenue guidance to $520 million to $540 million, reflecting strong growth expectations, particularly from the gout expansion.
ANI Pharmaceuticals stock falls 7% despite second quarter beat
ANI Pharmaceuticals Inc. reported better-than-expected second-quarter results but saw its stock fall 7.60% in pre-market trading. This decline was primarily due to the company lowering its full-year guidance for its key Cortrophin Gel product, despite reaffirming overall full-year revenue and adjusted EBITDA/EPS guidance. The company highlighted strong financial performance and positive leading indicators from its Cortrophin Gel sales force expansion.
Earnings Flash (ANIP) ANI Pharmaceuticals, Inc. Reports Q2 Revenue $266.0M, vs. FactSet Est of $260.1M
ANI Pharmaceuticals, Inc. (ANIP) reported its Q2 revenue of $266.0 million, surpassing the FactSet estimate of $260.1 million. The company also announced Q2 adjusted EPS of $2.21 per share, exceeding the FactSet estimate of $2.04. Furthermore, ANI Pharmaceuticals expects 2026 net revenue in the range of $1.08B - $1.14B and adjusted EPS between $9.19 - $9.69, both aligning with or surpassing analyst estimates.
Earnings Flash (ANIP) ANI Pharmaceuticals, Inc. Posts Q2 Adjusted EPS $2.21 per Share, vs. FactSet Est of $2.04
ANI Pharmaceuticals, Inc. (ANIP) reported Q2 adjusted EPS of $2.21 per share, surpassing FactSet's estimate of $2.04. The company's adjusted earnings and revenue both rose in Q2. Additionally, ANI Pharmaceuticals expects 2026 net revenue to range between $1.08 billion and $1.14 billion and adjusted EPS to be between $9.19 and $9.69, both exceeding FactSet estimates.
ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
ANI Pharmaceuticals, Inc. announced record financial results for the second quarter of 2026, with total net revenues increasing by 25.9% year-over-year to $266.0 million and adjusted non-GAAP EBITDA rising by 32.4% to $71.6 million. The company reaffirmed its full-year 2026 guidance for total net revenue and adjusted non-GAAP EBITDA, driven by strong performance in its Rare Disease segment, particularly Cortrophin Gel, and robust Generics sales. ANI also highlighted the successful expansion of its sales force for Cortrophin Gel in acute gouty arthritis flares and ongoing new product launches in its Generics business.
ANI Pharmaceuticals earnings on deck as rare disease shift accelerates By Investing.com
ANI Pharmaceuticals is set to report Q2 earnings, with investors focusing on the company's shift towards rare disease treatments, particularly Cortrophin Gel. Analysts predict $2.05 EPS on $260.85 million revenue, and the market will scrutinize Cortrophin's sustained momentum, profitability amidst rising royalties and operating expenses, and the performance of the generics business. The report will test whether ANI can maintain its upbeat full-year guidance despite potential challenges.
Janus Henderson Group PLC Grows Stake in ANI Pharmaceuticals, Inc. $ANIP
Janus Henderson Group PLC significantly increased its stake in ANI Pharmaceuticals, Inc. during the first quarter of 2026, boosting its holdings by 1,308.1% to 109,552 shares valued at approximately $8.4 million. This move comes as ANI Pharmaceuticals reported strong quarterly earnings, beating analyst estimates with $2.05 EPS and a 20.5% year-over-year revenue increase. Despite substantial institutional ownership and a "Moderate Buy" consensus rating from analysts, there have been significant insider stock sales totaling $7.0 million over the past quarter.
ANI Pharmaceuticals (ANIP) to Release Quarterly Earnings on Friday
ANI Pharmaceuticals (ANIP) is scheduled to release its Q2 2026 earnings before market open on Friday, August 7th. Analysts project earnings of $2.01 per share and revenue of $260.13 million. The company surpassed analyst expectations in its previous quarter, reporting $2.05 EPS against an estimate of $1.28, with revenue up 20.5% year-over-year.
ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth
ANI Pharmaceuticals (ANIP) is expected to report a year-over-year increase in earnings and higher revenues for the quarter ended June 2026. Despite a positive Earnings ESP, the stock's Zacks Rank #4 makes it difficult to definitively predict an earnings beat. Investors are advised to consider other factors alongside these indicators.
ANI Pharmaceuticals (ANIP) SVP & CFO Stephen Carey Sells 2,850 S
Stephen Carey, SVP & CFO of ANI Pharmaceuticals (ANIP), sold 2,850 shares of the company on July 29, 2026, for approximately $231,876. This sale contributes to a year-long trend of insider selling at ANI Pharmaceuticals, with no insider buys. Despite the selling, GuruFocus's GF Value suggests the stock is modestly undervalued, trading approximately 19% below its intrinsic worth.
ANI Pharmaceuticals (NASDAQ:ANIP) CFO Sells 2,850 Shares of Stock
ANI Pharmaceuticals' (NASDAQ:ANIP) CFO Stephen Carey sold 2,850 shares of the company's stock for $231,876, reducing his stake by 1.61%. Despite this insider sale, the company reported strong Q1 earnings, beating analyst expectations with 20.5% year-over-year revenue growth. Analysts maintain a "Moderate Buy" rating for ANIP, with an average price target of $105.
ANI Pharmaceuticals (ANIP) CFO Stephen Carey sells 2,850 shares in Rule 10b5-1 trades
ANI Pharmaceuticals' SVP & CFO, Stephen P. Carey, sold 2,850 shares of common stock on July 29, 2026, at a weighted average price of $81.36 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026. Following this sale, Carey directly holds 174,693 shares of ANI Pharmaceuticals common stock.
ANIP|ANI Pharmaceuticals Inc|Price:81.750|Chg%:+0.710
This article provides a detailed financial overview of ANI Pharmaceuticals Inc (ANIP), presenting its income statement, balance sheet, and cash flow statement. It highlights key financial indicators such as EPS, Revenue, Net Profit, and various margins, alongside projected earnings and revenue forecasts. The document also includes an analyst rating and answers frequently asked questions regarding the company's financial performance in FY2025.
ANI Pharmaceuticals (NASDAQ: ANIP) insider plans Form 144 sale of restricted shares
ANI Pharmaceuticals insider Stephen P. Carey has filed a Form 144 to sell 6,163 shares of common stock, valued at $499,449.52. These shares originate from Restricted Stock Awards granted on April 6, 2019, and the sale is planned for July 29, 2026, on NASDAQ. The filing also details previous Rule 10b5-1 sales by Carey, totaling 3,313 shares on July 2, 2026, 2,850 shares on June 29, 2026, and 3,312 shares on June 5, 2026.
ANIP|ANI Pharmaceuticals Inc|Price:79.255|Chg%:-1.175
This article provides a comprehensive stock analysis of ANI Pharmaceuticals Inc (ANIP) by TradingKey. It highlights the company's healthy fundamentals, high growth potential, and fair valuation within the pharmaceuticals industry. The analysis also covers institutional ownership, analyst ratings, and a detailed breakdown of how TradingKey calculates its various scores for financial health, valuation, earnings forecasts, price momentum, institutional confidence, and risk management.
ANI Pharmaceuticals, Inc. $ANIP Shares Purchased by Arrowstreet Capital Limited Partnership
Arrowstreet Capital Limited Partnership significantly increased its stake in ANI Pharmaceuticals (ANIP) by 19.3% in the first quarter, now owning 2.52% of the company's shares. This comes as ANI Pharmaceuticals reported strong quarterly results, exceeding EPS and revenue consensus estimates, and provided positive fiscal 2026 EPS guidance. Analysts maintain a "Moderate Buy" consensus for ANIP, with an average price target of $105.
ANI Pharmaceuticals Inc (ANIP) Institutional Confidence
ANI Pharmaceuticals Inc (ANIP) has an institutional shareholding score of 10.00, placing it first in the Pharmaceuticals industry. The institutional shareholding proportion is 101.74%, showing a 1.25% quarter-over-quarter increase. James Simons is the largest institutional shareholder, holding 0.87% of shares outstanding.
ANI Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data
ANI Pharmaceuticals (NASDAQ: ANIP) has approximately 1,030 employees worldwide as of March 2026, marking a 17.1% growth since 2023. The company is actively hiring, with 60 job postings in 2026, and its workforce is primarily concentrated in North America, with an average salary of $84,315. Employee sentiment is neutral but improving.
How Ani Pharmaceuticals Inc. (ANIP) Affects Rotational Strategy Timing
This article analyzes Ani Pharmaceuticals Inc. (ANIP) using AI models to suggest trading strategies. It highlights a near-term neutral sentiment and a mid-channel oscillation pattern, with an exceptional risk-reward setup targeting an 8.9% gain. The report outlines position, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis for different holding periods.
How Ani Pharmaceuticals Inc. (ANIP) Affects Rotational Strategy Timing
The article analyzes Ani Pharmaceuticals Inc. (ANIP) through quantitative research, highlighting a near-term neutral sentiment amidst mid and long-term weakness. It details specific trading strategies—Position, Momentum Breakout, and Risk Hedging—with defined entry points, targets, and stop losses. The analysis also provides multi-timeframe signal insights, suggesting ANIP has an exceptional 31.1:1 risk-reward setup.
ANI Pharmaceuticals Inc (ANIP) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of ANI Pharmaceuticals Inc (ANIP), listing its major shareholders and their respective proportions. It also provides a breakdown of shareholder types by proportion and presents institutional shareholding trends over several quarters, including changes in the number of institutions and shares held. The report also lists related ETFs that hold ANIP.
BlackRock (ANIP) discloses 2.9M-share, 12.8% stake in ANI Pharmaceuticals
BlackRock, Inc. has filed an amended beneficial ownership report, disclosing a 12.8% stake in ANI Pharmaceuticals Inc. (ANIP). BlackRock's business units collectively beneficially own 2,899,843 shares of ANI Pharmaceuticals common stock, with sole voting power over 2,860,943 shares and sole dispositive power over all 2,899,843 shares. This filing is a Schedule 13G/A, indicating a passive investment.
Principal Financial Group Inc. Has $9.93 Million Stake in ANI Pharmaceuticals, Inc. $ANIP
Principal Financial Group Inc. increased its stake in ANI Pharmaceuticals, Inc. by 19.1% in the first quarter, now holding 129,148 shares valued at $9.93 million. The specialty pharmaceutical company reported strong quarterly results, with EPS of $2.05 exceeding expectations and revenue up 20.5% year over year. Despite notable insider selling, analysts rate the stock a Moderate Buy with an average target price of $105.00.
TradingKey
This article provides a comprehensive quarterly and annual income statement for ANI Pharmaceuticals Inc (ANIP) up to FY2026Q1, detailing key financial metrics such as total revenue, cost of revenue, operating expenses, and net income. It also includes an FAQ section explaining how to read an income statement and defines important metrics for investors. The data aims to offer insights into ANI Pharmaceuticals Inc's financial performance and operational efficiency.
ANI Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ANIP
This article provides a revenue breakdown for ANI Pharmaceuticals, Inc. (ANIP) for the last fiscal year. The company generated $883.37 million in revenue, with its Rare Disease and Brands segment contributing $483.93 million. The United States was the primary source of revenue, accounting for $852.44 million.
ANI Pharmaceuticals (NasdaqGM:ANIP) Stock Forecast & Analyst Predictions
ANI Pharmaceuticals is projected to grow earnings by 24% and revenue by 9.6% annually, with EPS growth of 13.8% and a forecasted 25.4% return on equity in three years. The company has frequently raised its revenue guidance for 2025 and 2026 and recently announced positive results from its SYNCHRONICITY trial and a $100 million share buyback program. Insider transactions show more selling than buying in the past year, while analysts have adjusted price targets based on updated revenue, margin, and P/E expectations.
